Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial

Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial

Saved in:
Bibliographic Details
Published in:European urology
Main Authors: Pal, Sumanta K., Grivas, Petros, Gupta, Shilpa, Dizman, Nazli, Zengin, Zeynep, Valderrama, Begona P., Rodriguez-Vida, Alejo, Roghmann, Florian, Sevillano Fernandez, Elena, Matin, Surena F., Loriot, Yohann, Sridhar, Srikala S., Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Bellmunt, Joaquim, Master, Viraj, Tripathi, Abhishek, Davis, Kim, van Veenhuyzen, David, Weng, Richard, Daneshmand, Siamak
Format: Journal Article
Language:English
Published: Switzerland Elsevier B.V 04-04-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2024.03.023